Medical Care
Global Benign Prostatic Hyperplasia Therapeutics Market Research Report 2024
- Jan 20, 24
- ID: 16006
- Pages: 86
- Figures: 163
- Views: 29
Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease
The global Benign Prostatic Hyperplasia Therapeutics market was valued at US$ 6476.6 million in 2023 and is anticipated to reach US$ 8438.6 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia Therapeutics.
Report Scope
The Benign Prostatic Hyperplasia Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH and Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck and Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited
Segment by Type
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Segment by Application
Mono Drug Therapy
Combination Drug Therapy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Benign Prostatic Hyperplasia Therapeutics market was valued at US$ 6476.6 million in 2023 and is anticipated to reach US$ 8438.6 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia Therapeutics.
Report Scope
The Benign Prostatic Hyperplasia Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH and Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck and Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited
Segment by Type
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Segment by Application
Mono Drug Therapy
Combination Drug Therapy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Alpha Blocker
1.2.3 5-Alpha Reductase Inhibitor
1.2.4 Phosphodiesterase-5 Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Mono Drug Therapy
1.3.3 Combination Drug Therapy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Perspective (2019-2030)
2.2 Benign Prostatic Hyperplasia Therapeutics Growth Trends by Region
2.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Benign Prostatic Hyperplasia Therapeutics Market Dynamics
2.3.1 Benign Prostatic Hyperplasia Therapeutics Industry Trends
2.3.2 Benign Prostatic Hyperplasia Therapeutics Market Drivers
2.3.3 Benign Prostatic Hyperplasia Therapeutics Market Challenges
2.3.4 Benign Prostatic Hyperplasia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Therapeutics Revenue
3.4 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Therapeutics Revenue in 2023
3.5 Benign Prostatic Hyperplasia Therapeutics Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Therapeutics Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2025-2030)
5 Benign Prostatic Hyperplasia Therapeutics Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
6.2 North America Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
6.4 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
7.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
7.4 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
9.2 Latin America Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Introduction
11.1.4 Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Allergan plc
11.2.1 Allergan plc Company Detail
11.2.2 Allergan plc Business Overview
11.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Introduction
11.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.2.5 Allergan plc Recent Development
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Detail
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.3.5 Astellas Pharma Recent Development
11.4 Boehringer Ingelheim Pharma GmbH and Co. KG
11.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Company Detail
11.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
11.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Introduction
11.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Detail
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Introduction
11.5.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.5.5 Eli Lilly and Company Recent Development
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Company Detail
11.6.2 GlaxoSmithKline plc Business Overview
11.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Introduction
11.6.4 GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.6.5 GlaxoSmithKline plc Recent Development
11.7 Merck and Co.
11.7.1 Merck and Co. Company Detail
11.7.2 Merck and Co. Business Overview
11.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Introduction
11.7.4 Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.7.5 Merck and Co. Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Introduction
11.8.4 Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Introduction
11.9.4 Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Limited
11.10.1 Teva Pharmaceutical Industries Limited Company Detail
11.10.2 Teva Pharmaceutical Industries Limited Business Overview
11.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Alpha Blocker
1.2.3 5-Alpha Reductase Inhibitor
1.2.4 Phosphodiesterase-5 Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Mono Drug Therapy
1.3.3 Combination Drug Therapy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Perspective (2019-2030)
2.2 Benign Prostatic Hyperplasia Therapeutics Growth Trends by Region
2.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Benign Prostatic Hyperplasia Therapeutics Market Dynamics
2.3.1 Benign Prostatic Hyperplasia Therapeutics Industry Trends
2.3.2 Benign Prostatic Hyperplasia Therapeutics Market Drivers
2.3.3 Benign Prostatic Hyperplasia Therapeutics Market Challenges
2.3.4 Benign Prostatic Hyperplasia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Therapeutics Revenue
3.4 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Therapeutics Revenue in 2023
3.5 Benign Prostatic Hyperplasia Therapeutics Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Therapeutics Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2025-2030)
5 Benign Prostatic Hyperplasia Therapeutics Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
6.2 North America Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
6.4 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
7.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
7.4 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
9.2 Latin America Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Introduction
11.1.4 Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Allergan plc
11.2.1 Allergan plc Company Detail
11.2.2 Allergan plc Business Overview
11.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Introduction
11.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.2.5 Allergan plc Recent Development
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Detail
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.3.5 Astellas Pharma Recent Development
11.4 Boehringer Ingelheim Pharma GmbH and Co. KG
11.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Company Detail
11.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
11.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Introduction
11.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Detail
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Introduction
11.5.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.5.5 Eli Lilly and Company Recent Development
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Company Detail
11.6.2 GlaxoSmithKline plc Business Overview
11.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Introduction
11.6.4 GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.6.5 GlaxoSmithKline plc Recent Development
11.7 Merck and Co.
11.7.1 Merck and Co. Company Detail
11.7.2 Merck and Co. Business Overview
11.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Introduction
11.7.4 Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.7.5 Merck and Co. Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Introduction
11.8.4 Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Introduction
11.9.4 Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Limited
11.10.1 Teva Pharmaceutical Industries Limited Company Detail
11.10.2 Teva Pharmaceutical Industries Limited Business Overview
11.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Alpha Blocker
Table 3. Key Players of 5-Alpha Reductase Inhibitor
Table 4. Key Players of Phosphodiesterase-5 Inhibitor
Table 5. Key Players of Others
Table 6. Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region (2019-2024)
Table 10. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region (2025-2030)
Table 12. Benign Prostatic Hyperplasia Therapeutics Market Trends
Table 13. Benign Prostatic Hyperplasia Therapeutics Market Drivers
Table 14. Benign Prostatic Hyperplasia Therapeutics Market Challenges
Table 15. Benign Prostatic Hyperplasia Therapeutics Market Restraints
Table 16. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Players (2019-2024)
Table 18. Global Top Benign Prostatic Hyperplasia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2023)
Table 19. Ranking of Global Top Benign Prostatic Hyperplasia Therapeutics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
Table 23. Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type (2019-2024)
Table 27. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type (2025-2030)
Table 29. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application (2019-2024)
Table 31. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application (2025-2030)
Table 33. North America Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Abbott Laboratories Company Detail
Table 49. Abbott Laboratories Business Overview
Table 50. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product
Table 51. Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 52. Abbott Laboratories Recent Development
Table 53. Allergan plc Company Detail
Table 54. Allergan plc Business Overview
Table 55. Allergan plc Benign Prostatic Hyperplasia Therapeutics Product
Table 56. Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 57. Allergan plc Recent Development
Table 58. Astellas Pharma Company Detail
Table 59. Astellas Pharma Business Overview
Table 60. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product
Table 61. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 62. Astellas Pharma Recent Development
Table 63. Boehringer Ingelheim Pharma GmbH and Co. KG Company Detail
Table 64. Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
Table 65. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product
Table 66. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 67. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Development
Table 68. Eli Lilly and Company Company Detail
Table 69. Eli Lilly and Company Business Overview
Table 70. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product
Table 71. Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 72. Eli Lilly and Company Recent Development
Table 73. GlaxoSmithKline plc Company Detail
Table 74. GlaxoSmithKline plc Business Overview
Table 75. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product
Table 76. GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 77. GlaxoSmithKline plc Recent Development
Table 78. Merck and Co. Company Detail
Table 79. Merck and Co. Business Overview
Table 80. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product
Table 81. Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 82. Merck and Co. Recent Development
Table 83. Pfizer Company Detail
Table 84. Pfizer Business Overview
Table 85. Pfizer Benign Prostatic Hyperplasia Therapeutics Product
Table 86. Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 87. Pfizer Recent Development
Table 88. Sanofi Company Detail
Table 89. Sanofi Business Overview
Table 90. Sanofi Benign Prostatic Hyperplasia Therapeutics Product
Table 91. Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 92. Sanofi Recent Development
Table 93. Teva Pharmaceutical Industries Limited Company Detail
Table 94. Teva Pharmaceutical Industries Limited Business Overview
Table 95. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product
Table 96. Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 97. Teva Pharmaceutical Industries Limited Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostatic Hyperplasia Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Alpha Blocker Features
Figure 4. 5-Alpha Reductase Inhibitor Features
Figure 5. Phosphodiesterase-5 Inhibitor Features
Figure 6. Others Features
Figure 7. Global Benign Prostatic Hyperplasia Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Mono Drug Therapy Case Studies
Figure 10. Combination Drug Therapy Case Studies
Figure 11. Benign Prostatic Hyperplasia Therapeutics Report Years Considered
Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Benign Prostatic Hyperplasia Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region: 2023 VS 2030
Figure 15. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Players in 2023
Figure 16. Global Top Benign Prostatic Hyperplasia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue in 2023
Figure 18. North America Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Benign Prostatic Hyperplasia Therapeutics Market Share by Country (2019-2030)
Figure 20. United States Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Benign Prostatic Hyperplasia Therapeutics Market Share by Country (2019-2030)
Figure 24. Germany Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Share by Region (2019-2030)
Figure 32. China Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Benign Prostatic Hyperplasia Therapeutics Market Share by Country (2019-2030)
Figure 40. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Share by Country (2019-2030)
Figure 44. Turkey Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Abbott Laboratories Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 47. Allergan plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 48. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 49. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 50. Eli Lilly and Company Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 51. GlaxoSmithKline plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 52. Merck and Co. Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 53. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 54. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 55. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Table 1. Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Alpha Blocker
Table 3. Key Players of 5-Alpha Reductase Inhibitor
Table 4. Key Players of Phosphodiesterase-5 Inhibitor
Table 5. Key Players of Others
Table 6. Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region (2019-2024)
Table 10. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region (2025-2030)
Table 12. Benign Prostatic Hyperplasia Therapeutics Market Trends
Table 13. Benign Prostatic Hyperplasia Therapeutics Market Drivers
Table 14. Benign Prostatic Hyperplasia Therapeutics Market Challenges
Table 15. Benign Prostatic Hyperplasia Therapeutics Market Restraints
Table 16. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Players (2019-2024)
Table 18. Global Top Benign Prostatic Hyperplasia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2023)
Table 19. Ranking of Global Top Benign Prostatic Hyperplasia Therapeutics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
Table 23. Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type (2019-2024)
Table 27. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type (2025-2030)
Table 29. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application (2019-2024)
Table 31. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application (2025-2030)
Table 33. North America Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Abbott Laboratories Company Detail
Table 49. Abbott Laboratories Business Overview
Table 50. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product
Table 51. Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 52. Abbott Laboratories Recent Development
Table 53. Allergan plc Company Detail
Table 54. Allergan plc Business Overview
Table 55. Allergan plc Benign Prostatic Hyperplasia Therapeutics Product
Table 56. Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 57. Allergan plc Recent Development
Table 58. Astellas Pharma Company Detail
Table 59. Astellas Pharma Business Overview
Table 60. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product
Table 61. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 62. Astellas Pharma Recent Development
Table 63. Boehringer Ingelheim Pharma GmbH and Co. KG Company Detail
Table 64. Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
Table 65. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product
Table 66. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 67. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Development
Table 68. Eli Lilly and Company Company Detail
Table 69. Eli Lilly and Company Business Overview
Table 70. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product
Table 71. Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 72. Eli Lilly and Company Recent Development
Table 73. GlaxoSmithKline plc Company Detail
Table 74. GlaxoSmithKline plc Business Overview
Table 75. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product
Table 76. GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 77. GlaxoSmithKline plc Recent Development
Table 78. Merck and Co. Company Detail
Table 79. Merck and Co. Business Overview
Table 80. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product
Table 81. Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 82. Merck and Co. Recent Development
Table 83. Pfizer Company Detail
Table 84. Pfizer Business Overview
Table 85. Pfizer Benign Prostatic Hyperplasia Therapeutics Product
Table 86. Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 87. Pfizer Recent Development
Table 88. Sanofi Company Detail
Table 89. Sanofi Business Overview
Table 90. Sanofi Benign Prostatic Hyperplasia Therapeutics Product
Table 91. Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 92. Sanofi Recent Development
Table 93. Teva Pharmaceutical Industries Limited Company Detail
Table 94. Teva Pharmaceutical Industries Limited Business Overview
Table 95. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product
Table 96. Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024) & (US$ Million)
Table 97. Teva Pharmaceutical Industries Limited Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostatic Hyperplasia Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Alpha Blocker Features
Figure 4. 5-Alpha Reductase Inhibitor Features
Figure 5. Phosphodiesterase-5 Inhibitor Features
Figure 6. Others Features
Figure 7. Global Benign Prostatic Hyperplasia Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Mono Drug Therapy Case Studies
Figure 10. Combination Drug Therapy Case Studies
Figure 11. Benign Prostatic Hyperplasia Therapeutics Report Years Considered
Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Benign Prostatic Hyperplasia Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region: 2023 VS 2030
Figure 15. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Players in 2023
Figure 16. Global Top Benign Prostatic Hyperplasia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue in 2023
Figure 18. North America Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Benign Prostatic Hyperplasia Therapeutics Market Share by Country (2019-2030)
Figure 20. United States Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Benign Prostatic Hyperplasia Therapeutics Market Share by Country (2019-2030)
Figure 24. Germany Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Share by Region (2019-2030)
Figure 32. China Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Benign Prostatic Hyperplasia Therapeutics Market Share by Country (2019-2030)
Figure 40. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Share by Country (2019-2030)
Figure 44. Turkey Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Abbott Laboratories Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 47. Allergan plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 48. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 49. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 50. Eli Lilly and Company Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 51. GlaxoSmithKline plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 52. Merck and Co. Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 53. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 54. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 55. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232